184 related articles for article (PubMed ID: 25041274)
1. Humoral immune response as predictor of recurrence in Clostridium difficile infection.
Bauer MP; Nibbering PH; Poxton IR; Kuijper EJ; van Dissel JT
Clin Microbiol Infect; 2014 Dec; 20(12):1323-8. PubMed ID: 25041274
[TBL] [Abstract][Full Text] [Related]
2. Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors.
von Eichel-Streiber A; Paik W; Knight K; Gisch K; Nadjafi K; Decker C; Bosnjak O; Cheknis A; Johnson S; von Eichel-Streiber C
Anaerobe; 2016 Oct; 41():91-103. PubMed ID: 27427464
[TBL] [Abstract][Full Text] [Related]
3. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
[TBL] [Abstract][Full Text] [Related]
4. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
[TBL] [Abstract][Full Text] [Related]
5. Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses.
Solomon K; Martin AJ; O'Donoghue C; Chen X; Fenelon L; Fanning S; Kelly CP; Kyne L
J Med Microbiol; 2013 Sep; 62(Pt 9):1453-1460. PubMed ID: 23722431
[TBL] [Abstract][Full Text] [Related]
6. Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis.
Negm OH; Hamed MR; Dilnot EM; Shone CC; Marszalowska I; Lynch M; Loscher CE; Edwards LJ; Tighe PJ; Wilcox MH; Monaghan TM
Clin Vaccine Immunol; 2015 Sep; 22(9):1033-9. PubMed ID: 26178385
[TBL] [Abstract][Full Text] [Related]
7. Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.
Yang Z; Shi L; Yu H; Zhang Y; Chen K; Saint Fleur A; Bai G; Feng H
Pathog Dis; 2016 Oct; 74(7):. PubMed ID: 27502696
[TBL] [Abstract][Full Text] [Related]
8. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
Kyne L; Warny M; Qamar A; Kelly CP
N Engl J Med; 2000 Feb; 342(6):390-7. PubMed ID: 10666429
[TBL] [Abstract][Full Text] [Related]
9. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.
Guo S; Yan W; McDonough SP; Lin N; Wu KJ; He H; Xiang H; Yang M; Moreira MA; Chang YF
Vaccine; 2015 Mar; 33(13):1586-95. PubMed ID: 25698490
[TBL] [Abstract][Full Text] [Related]
10. Development of a new serological assay for the diagnosis of Clostridium difficile infections with prognostic value.
von Bechtolsheim F; Varga A; Szereday L; Polgar B; Balassa T; Kocsis B; Peterfi Z; Miko E
J Microbiol Methods; 2019 Dec; 167():105777. PubMed ID: 31733265
[TBL] [Abstract][Full Text] [Related]
11. Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.
Hughes M; Qazi T; Berg A; Weinberg J; Chen X; Kelly CP; Farraye FA
Inflamm Bowel Dis; 2016 Apr; 22(4):853-61. PubMed ID: 26954708
[TBL] [Abstract][Full Text] [Related]
12. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY
BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596
[TBL] [Abstract][Full Text] [Related]
13. Clostridium difficile antibodies: a patent evaluation (WO2013028810).
Lo Vecchio A; Della Ventura B; Nicastro E
Expert Opin Ther Pat; 2013 Dec; 23(12):1635-40. PubMed ID: 23978053
[TBL] [Abstract][Full Text] [Related]
14. Anti-toxin antibody is not associated with recurrent Clostridium difficile infection.
Gilbert J; Leslie J; Putler R; Weiner S; Standke A; Penkevich A; Keidan M; Young VB; Rao K
Anaerobe; 2021 Feb; 67():102299. PubMed ID: 33227427
[TBL] [Abstract][Full Text] [Related]
15. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
[TBL] [Abstract][Full Text] [Related]
16. The role of the humoral immune response to Clostridium difficile toxins A and B in susceptibility to C. difficile infection: a case-control study.
Islam J; Taylor AL; Rao K; Huffnagle G; Young VB; Rajkumar C; Cohen J; Papatheodorou P; Aronoff DM; Llewelyn MJ
Anaerobe; 2014 Jun; 27():82-6. PubMed ID: 24708941
[TBL] [Abstract][Full Text] [Related]
17. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).
Leav BA; Blair B; Leney M; Knauber M; Reilly C; Lowy I; Gerding DN; Kelly CP; Katchar K; Baxter R; Ambrosino D; Molrine D
Vaccine; 2010 Jan; 28(4):965-9. PubMed ID: 19941990
[TBL] [Abstract][Full Text] [Related]
18. Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection.
Zhao X; Bender F; Shukla R; Kang JJ; Caro-Aguilar I; Laterza OF
Bioanalysis; 2016 Apr; 8(7):611-23. PubMed ID: 26964649
[TBL] [Abstract][Full Text] [Related]
19. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.
Zhang Z; Chen X; Hernandez LD; Lipari P; Flattery A; Chen SC; Kramer S; Polishook JD; Racine F; Cape H; Kelly CP; Therien AG
Infect Immun; 2015 Jan; 83(1):405-16. PubMed ID: 25385797
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
